Translational Medicine and Drug Discovery
Herausgeber: Krishna, Rajesh; Littman, Bruce H.
Translational Medicine and Drug Discovery
Herausgeber: Krishna, Rajesh; Littman, Bruce H.
- Gebundenes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
This book focuses on the new discipline of translational medicine as it pertains to drug development within the pharmaceutical and biotechnology industry.
Andere Kunden interessierten sich auch für
- Translational Medicine and Drug Discovery72,99 €
- Bioactive Natural Products in Drug Discovery156,99 €
- Chemoinformatics in Drug Design and Discovery155,99 €
- Structural Genomics and Drug Discovery110,99 €
- Translational Vascular Medicine110,99 €
- Translational Medicine174,99 €
- Structural Genomics and Drug Discovery81,99 €
-
-
-
This book focuses on the new discipline of translational medicine as it pertains to drug development within the pharmaceutical and biotechnology industry.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Produktdetails
- Produktdetails
- Verlag: Cambridge University Press
- Seitenzahl: 384
- Erscheinungstermin: 2. März 2015
- Englisch
- Abmessung: 260mm x 183mm x 25mm
- Gewicht: 915g
- ISBN-13: 9780521886451
- ISBN-10: 0521886457
- Artikelnr.: 32924795
- Verlag: Cambridge University Press
- Seitenzahl: 384
- Erscheinungstermin: 2. März 2015
- Englisch
- Abmessung: 260mm x 183mm x 25mm
- Gewicht: 915g
- ISBN-13: 9780521886451
- ISBN-10: 0521886457
- Artikelnr.: 32924795
Part I. Translational Medicine: History, Principles and Application in Drug
Development: 1. Overview of translational medicine and drug development
Bruce H. Littman; 2. Concepts and case studies: diabetes Ann Taylor and
Roberto Calle; 3. Challenges in atherosclerosis John Millar; 4. Obesity:
new mechanisms and translational paradigms Gregory Gaich and David E.
Moller; 5. Bone disorders: case studies of translational research S. Aubrey
Stoch; 6. Case studies in neuroscience: unique challenges and examples
Gerard J. Marek; 7. Translational medicine in oncology Dominic G. Spinella;
Part II. Biomarkers and Public-Private Partnerships: 8. Biomarker
validation and application in drug development Pfizer Global Research and
Development; 9. Application of imaging methods in translational medicine
Johannes T. Tauscher and Adam Schwarz; 10. European innovative medicines
initiative Ole J. Bjerrum and Hans H. Linden; 11. Critical path institute
and the predictive safety consortium Elizabeth Gribble Walker; 12. The
biomarker consortium David B. Lee; Part III. Future Directions: 13.
Improving the quality and productivity of pharmacometric modeling and
simulation activities - the foundation for model-based drug development
Thaddeus H. Grasela, Jill Fiedler-Kelly and Robert Slusser; 14. Embracing
change: a pharmaceutical industry guide to the 21st century Mervyn Turner.
Development: 1. Overview of translational medicine and drug development
Bruce H. Littman; 2. Concepts and case studies: diabetes Ann Taylor and
Roberto Calle; 3. Challenges in atherosclerosis John Millar; 4. Obesity:
new mechanisms and translational paradigms Gregory Gaich and David E.
Moller; 5. Bone disorders: case studies of translational research S. Aubrey
Stoch; 6. Case studies in neuroscience: unique challenges and examples
Gerard J. Marek; 7. Translational medicine in oncology Dominic G. Spinella;
Part II. Biomarkers and Public-Private Partnerships: 8. Biomarker
validation and application in drug development Pfizer Global Research and
Development; 9. Application of imaging methods in translational medicine
Johannes T. Tauscher and Adam Schwarz; 10. European innovative medicines
initiative Ole J. Bjerrum and Hans H. Linden; 11. Critical path institute
and the predictive safety consortium Elizabeth Gribble Walker; 12. The
biomarker consortium David B. Lee; Part III. Future Directions: 13.
Improving the quality and productivity of pharmacometric modeling and
simulation activities - the foundation for model-based drug development
Thaddeus H. Grasela, Jill Fiedler-Kelly and Robert Slusser; 14. Embracing
change: a pharmaceutical industry guide to the 21st century Mervyn Turner.
Part I. Translational Medicine: History, Principles and Application in Drug
Development: 1. Overview of translational medicine and drug development
Bruce H. Littman; 2. Concepts and case studies: diabetes Ann Taylor and
Roberto Calle; 3. Challenges in atherosclerosis John Millar; 4. Obesity:
new mechanisms and translational paradigms Gregory Gaich and David E.
Moller; 5. Bone disorders: case studies of translational research S. Aubrey
Stoch; 6. Case studies in neuroscience: unique challenges and examples
Gerard J. Marek; 7. Translational medicine in oncology Dominic G. Spinella;
Part II. Biomarkers and Public-Private Partnerships: 8. Biomarker
validation and application in drug development Pfizer Global Research and
Development; 9. Application of imaging methods in translational medicine
Johannes T. Tauscher and Adam Schwarz; 10. European innovative medicines
initiative Ole J. Bjerrum and Hans H. Linden; 11. Critical path institute
and the predictive safety consortium Elizabeth Gribble Walker; 12. The
biomarker consortium David B. Lee; Part III. Future Directions: 13.
Improving the quality and productivity of pharmacometric modeling and
simulation activities - the foundation for model-based drug development
Thaddeus H. Grasela, Jill Fiedler-Kelly and Robert Slusser; 14. Embracing
change: a pharmaceutical industry guide to the 21st century Mervyn Turner.
Development: 1. Overview of translational medicine and drug development
Bruce H. Littman; 2. Concepts and case studies: diabetes Ann Taylor and
Roberto Calle; 3. Challenges in atherosclerosis John Millar; 4. Obesity:
new mechanisms and translational paradigms Gregory Gaich and David E.
Moller; 5. Bone disorders: case studies of translational research S. Aubrey
Stoch; 6. Case studies in neuroscience: unique challenges and examples
Gerard J. Marek; 7. Translational medicine in oncology Dominic G. Spinella;
Part II. Biomarkers and Public-Private Partnerships: 8. Biomarker
validation and application in drug development Pfizer Global Research and
Development; 9. Application of imaging methods in translational medicine
Johannes T. Tauscher and Adam Schwarz; 10. European innovative medicines
initiative Ole J. Bjerrum and Hans H. Linden; 11. Critical path institute
and the predictive safety consortium Elizabeth Gribble Walker; 12. The
biomarker consortium David B. Lee; Part III. Future Directions: 13.
Improving the quality and productivity of pharmacometric modeling and
simulation activities - the foundation for model-based drug development
Thaddeus H. Grasela, Jill Fiedler-Kelly and Robert Slusser; 14. Embracing
change: a pharmaceutical industry guide to the 21st century Mervyn Turner.